ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Fibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic targets.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Physiologically, the FGFR signaling is essential for cell proliferation, differentiation, migration, and angiogenesis; yet its abnormal activation-via gene amplification, mutation, fusion, or overexpression-drives the development and progression of head and neck tumors. Although small‑molecule FGFR inhibitors have shown preliminary efficacy in some head and neck tumors, challenges such as molecular heterogeneity across tumor subtypes, drug resistance, and limited clinical evidence still hinder the precise application of targeted therapy. This review systematically summarizes the molecular mechanisms, clinicopathological correlations, and current targeted therapy status of the FGFR signaling pathway in nasopharyngeal carcinoma, salivary gland carcinoma, oral squamous cell carcinoma, thyroid carcinoma, laryngeal carcinoma, and ameloblastoma. It outlines a comprehensive framework of "genetic alterations-mechanistic regulation-clinical application" and aims to provide a theoretical reference for precision therapy of head and neck tumors.
Indexed as
Identifiers
42536330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.